

A convenient oral alternative to invasive continuous infusion in Parkinson's Disease.

## **Product**

Levodopum/carbidopum 5mg/1.25mg in dispersible minitablets. ATC: N04BA02

The only approved minitablet formulation for Parkinson's Disease.

Patent protected minitablet dispenser.

Allows for flexible and more frequent dosing of levodopa.

# **Regulatory Status**

Approved in: Sweden, Norway, Denmark, Finland, United Kingdom, Austria, Luxemburg, The Netherlands, Belgium and Poland.

Notified body approved decive.

### Reimbursed in:





Water-soluble tablets



Documented compliance



Effects in 20 minutes




Right dose at the right moment

#### **Manual Device**





# **Digital App**




Note: This product is not approved in Italy.

1	Unique treatment concept	Only provider of a treatment concept allowing for true individualization of each dose
2	Optimization of each dose	The system allows for an optimization and individualization of each dose – the risk of overdosing and related adverse events is minimized Dyskinesias as well as bradykinesisas minimized and QoL increased
3	Robust bioavailability	Flexilev® has a very robust bioavailability, not differing between healthy volunteers and patients
4	Robust and repeatable uptake	<ul> <li>Flexilev® has a robust and repeatable uptake/effect after multiple dosing</li> <li>The plasma levels after repeated doses are virtually identical, referring to both Cmax and Tmax</li> </ul>
5	Rapid onset	Flexilev® has a rapid onset (21 mins) – can be used for maintenance as well as rescue therapy
6	Frequent dosing	Dosing with Flexilev® is more frequent which is achieved with higher compliance

References upon request.

# Parkinson's Disease Treatment overview

# **Disease Progression**



#### **Other Treatment Options**

- Dopamine agonistsMAO inhibitors

#### **Invasive Treatments in Late stage**

- LD/CD intra-duodenal infusionDeep brain stimulationApomorphine pump

